共享集团(03344.HK)拟1271.66万港元收购大拓投资66%股权
格隆汇 7 月 7日丨共享集团(03344.HK)公告,于2020年7月7日,买方泽得发展有限公司(公司间接全资附属公司)与卖方羊老四订立收购协议,据此,买方同意根据收购协议的条款及条件收购而卖方同意出售目标公司大拓投资有限公司66%股份,代价为1271.66万港元。
目标公司为一间于香港注册成立的有限公司及从事投资控股。于公告日期,目标公司由卖方合法及实益全资拥有。于重组完成后,目标公司将持有该附属公司,即珠海远望腾达发展有限公司的全部股权,该公司为一间于中国成立的有限公司,主要于中国从事外科口罩生产及销售业务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.